Celcuity Inc. (NASDAQ:CELC) Receives Consensus Rating of “Buy” from Brokerages

Shares of Celcuity Inc. (NASDAQ:CELC) have earned a consensus rating of “Buy” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $28.67.

Several analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Celcuity in a research note on Thursday, August 15th. Leerink Partnrs upgraded Celcuity to a “strong-buy” rating in a research note on Monday, July 22nd. Leerink Partners assumed coverage on Celcuity in a research note on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Celcuity in a research note on Thursday, August 15th. Finally, Stifel Nicolaus cut their price objective on Celcuity from $40.00 to $39.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th.

Celcuity Stock Up 1.5 %

Shares of Celcuity stock opened at $15.04 on Friday. The business has a 50-day moving average of $15.89 and a 200-day moving average of $16.65. The company has a debt-to-equity ratio of 0.54, a current ratio of 14.95 and a quick ratio of 14.95. The company has a market capitalization of $527.92 million, a PE ratio of -5.41 and a beta of 0.75. Celcuity has a 1-year low of $8.39 and a 1-year high of $22.19.

Celcuity (NASDAQ:CELC) last announced its earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. During the same period last year, the company earned ($0.66) EPS. As a group, equities analysts forecast that Celcuity will post -2.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Celcuity

Several institutional investors have recently made changes to their positions in the stock. Quest Partners LLC grew its holdings in shares of Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after purchasing an additional 1,379 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Celcuity by 9.9% during the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock valued at $272,000 after purchasing an additional 1,500 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Celcuity by 7.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after purchasing an additional 1,600 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Celcuity by 78.5% during the first quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock valued at $193,000 after purchasing an additional 3,930 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Celcuity by 27.7% during the second quarter. Rhumbline Advisers now owns 32,464 shares of the company’s stock valued at $532,000 after purchasing an additional 7,049 shares during the last quarter. 63.33% of the stock is owned by institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.